Date Time
Mayo study differentiates what blood-based proteins indicate about brain cell loss
Two proteins that can be measured in the blood – plasma total tau and neurofilament light – are associated with brain cell loss that causes memory and thinking problems. Neurofilament light was more strongly related to worse cognition and neurodegeneration, compared to total tau, according to a preliminary Mayo Clinic study that will be presented in the Emerging Science program at the 2021 virtual American Academy of Neurology Annual Meeting.
Brain cell loss, or neurodegeneration, is a common characteristic of many disorders, including Alzheimer’s disease, vascular dementia and Lewy body dementia. However, the causes and location of neurodegeneration in the brain vary depending on the disease.
Eisai to Present Latest Data on Neurology Products and Pipelines at the American Academy of Neurology Annual Meeting
TOKYO, Apr 14, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that the company will conduct presentations, including the latest data of the investigational anti-amyloid beta (Abeta) protofibril antibody lecanemab (development code: BAN2401), its dual orexin receptor antagonist lemborexant (product name: Dayvigo) and its antiepileptic drug perampanel (product name: Fycompa), at the Virtual American Academy of Neurology (AAN 2021) Annual Meeting from April 17 to 22, 2021.
As major presentations, an oral presentation regarding lecanemab will be given on the preliminary analysis for results of changes in brain-A beta levels and amyloid-related imaging abnormalities-edema (ARIA-E) as observed in subjects of the ongoing open-label extension of the Phase II study (Study 201) for early Alzheimer s disease (AD) patients. Poster presentations regarding lemborexant ar